Senti Bio Receives $8 Million CIRM Grant to Advance Logic-Gated CAR-NK Cell Therapy for AML
Senti Biosciences, Inc., a leader in next-generation cell and gene therapies, has been awarded an $8 million grant by the California Institute for Regenerative Medicine (CIRM). This significant funding will propel the clinical development of SENTI-202, an innovative off-the-shelf CAR-NK cell therapy designed to treat relapsed/refractory hematologic malignancies, including acute myeloid leukemia (AML). Pioneering Cell […]